You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SUPERFIBRONECTIN--A NEW ANTIMETASTATIC AGENT

    SBC: TUMOREX, INC.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  2. TRINOMIAL BIVARIATE NEURAL NETWORKS FOR GIS ANALYSIS

    SBC: Pragmatica Corporation            Topic: N/A

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  3. ShH10-Mediated Long-Term Delivery of Neurotrophic Factors in Animal Models of Gla

    SBC: AVALANCHE BIOTECHNOLOGIES, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): The objective of this proposal is to examine the efficacy of a novel adeno-associated virus (AAV) variant, ShH10, expressing neurotrophic factors for the treatment of glaucoma. Glaucoma is the second leading cause of blindness with high associated societal costs, and is expected to grow. The hallmark of glaucoma is retinal ganglion cell (RGC) death, which leads ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  5. N/A

    SBC: Aracor            Topic: N/A

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  6. N/A

    SBC: Allos Therapeutics, Inc.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  7. Night Alert Prompting System

    SBC: AMRON CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term aim of this program of research is to develop a Night Alert Prompting System (NAPS) that can be used by caregivers of home-dwelling cognitively impaired (CI) individuals to prevent nighttime injuries and unattended exits, improve caregiver sleep, reduce caregiver worry, and thereby delay institutionalization of the CI individuals. The primary func ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  8. N/A

    SBC: APOLLO LIGHT SYSTEMS, INC.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  9. NOVEL THERAPEUTIC APPROACH TO PSORIASIS

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (Applicant's abstract): Psoriasis is a common, inflammatory disease of the skin characterized by hyper-proliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. Thiaz ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. Light Visor for Treating Jet Lag: Controlled Field Trial

    SBC: Bio-Brite, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Jet lag is a syndrome of behavioral, cognitive, and physical symptoms that result when travelers are exposed to a sudden shift of the day-night cycle. These symptoms impact on alertness and performance of airline and military personnel and the safety of the traveling public. They may also exacerbate medical and psychiatric illness, and frequent flyers may face ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government